INS and metabolic disease: Evidence on IGF-1 in relation to metabolic diseases is still controversial, i.e. low levels of IGF-1 have been suggested to have beneficial effects on glucose homeostasis and may also sensitise insulin actions, thereby decreasing metabolic disease risk [28].